Last Updated: August 9, 2026

Patent: 10,857,205

✉ Email this page to a colleague

Summary for Patent: 10,857,205

Title:	Use of a VEGF antagonist to treat angiogenic eye disorders
Abstract:	The present invention provides methods for treating angiogenic eye disorders by sequentially administering multiple doses of a VEGF antagonist to a patient. The methods of the present invention include the administration of multiple doses of a VEGF antagonist to a patient at a frequency of once every 8 or more weeks. The methods of the present invention are useful for the treatment of angiogenic eye disorders such as age related macular degeneration, diabetic retinopathy, diabetic macular edema, central retinal vein occlusion, branch retinal vein occlusion, and corneal neovascularization.
Inventor(s):	Yancopoulos George D.
Assignee:	Regeneron Pharmaceuticals, Inc.
Application Number:	US16055847
Patent Claims:	see list of patent claims
Patent landscape, scope, and claims summary:	error: insufficient information More… ↓ ⤷ Start Trial

Details for Patent 10,857,205

Glossary

Subscribe to access the full database, or Start Trial
Applicant	Tradename	Biologic Ingredient	Dosage Form	BLA	Approval Date	Patent No.	Expiredate
Regeneron Pharmaceuticals, Inc.	EYLEA	aflibercept	Injection	125387	November 18, 2011	10,857,205	2038-08-06
Regeneron Pharmaceuticals, Inc.	EYLEA	aflibercept	Injection	125387	August 16, 2018	10,857,205	2038-08-06
Regeneron Pharmaceuticals, Inc.	EYLEA HD	aflibercept	Injection	761355	August 18, 2023	10,857,205	2038-08-06
>Applicant	>Tradename	>Biologic Ingredient	>Dosage Form	>BLA	>Approval Date	>Patent No.	>Expiredate

International Patent Family for US Patent 10,857,205

Subscribe to access the full database, or Start Trial
Country	Patent Number	Estimated Expiration
World Intellectual Property Organization (WIPO)	2012097019	⤷ Start Trial
United States of America	10130681	⤷ Start Trial
United States of America	10828345	⤷ Start Trial
United States of America	10888601	⤷ Start Trial
United States of America	11253572	⤷ Start Trial
United States of America	11559564	⤷ Start Trial
>Country	>Patent Number	>Estimated Expiration

Make Better Decisions: Try a trial or see plans & pricing

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. We do not provide individual investment advice. This service is not registered with any financial regulatory agency. The information we publish is educational only and based on our opinions plus our models. By using DrugPatentWatch you acknowledge that we do not provide personalized recommendations or advice. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.